Transgene’s programs utilize viral vector technology with the goal of indirectly or directly killing cancer cells.

The French company’s clinical-stage programs consist of a portfolio of therapeutic vaccines and oncolytic viruses.

They include TG4050, the first individualized therapeutic vaccine based on the myvac platform, TG4001 for the treatment of HPV-positive cancers, as well as TG6002, BT-001 and TG6050, three oncolytic viruses based on the Invir.IO viral backbone.